Deerfield Management Company, L.P. (Series C) Aerovate Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,411,608 shares of AVTE stock, worth $2.68 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
1,411,608Holding current value
$2.68 Million% of portfolio
0.05%Shares
3 transactions
Others Institutions Holding AVTE
# of Institutions
94Shares Held
27.7MCall Options Held
185KPut Options Held
129K-
Ra Capital Management, L.P. Boston, MA9.19MShares$17.5 Million0.23% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$7.14 Million0.35% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$4.26 Million0.56% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$3.42 Million0.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.11MShares$2.1 Million0.0% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $46.5M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...